// App-Quantinova.ai

2530 : A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies.

Researchers

Presenter

  • Matthew Hitron

Principal Investigators

  • Joe Stephenson

  • Youzhi Li

  • Wei Li

  • Keyur Gada

  • Chiang Li

  • Kim N. Chi

  • William Jeffery Edenfield

  • David Leggett

Medical Centers

  • Boston Biomedical Inc., Cambridge, MA

  • Boston Biomedical, Inc., Cambridge, MABC Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, CanadaCancer Centers of the Carolinas, Greenville, SC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Paclitaxel

  • BBI-608

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01325441

Sponsors

  • Boston Biomedical, Inc.

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved